Concord Kirin announces launch of Parkinson's new drug Nourianz in US

recently, Japan Pharmaceutical Company Concord and Kirin announced the launch of the new Parkinson'sdrug(http://Nourianz (http:// in the United StatesNourianz was approved by the U.SFDA(http://at the end of August 2019 as an additional therapy for adult patients with Parkinson's disease (PD) who are experiencing a "OFF" eventIn December 2018, Acorda(http://Product seints(http://Inbrija (Left-handed Doba Inhalation Powder) was approved by the U.SFDA for intermittent treatment of PD "OFF" events for Patients treated with Carbidoba/Left-spin dobaInbrija is the FDA-approved first inhaled levodopa, acombination ofdrug(http://-
device(http:// that allows patients to deliver their own hand-held medicinesInbrija has been developed using Acorda's proprietary ARCUS platform to provide accurate doses of l-doba dry powder preparations to the patient's lungsIn oral cases, the drug is absorbed through the stomach before reaching the brain, so the process of starting the action changesInhalation therapy can enter the body through the lungs, reaching directly into the brain and bypassing the digestive systemabout the tradefyllineistradefylline is an oral administration of selective adenosine A2A receptor antagonists, adenosine is a widely distributed in the human body neuromodulator, adenosine A2A receptor belongs to the G protein conjugate receptorIn the brain, adenosine A2A receptors are found in the fundamental synostic nerveThe effectiveness of the basal nerve section inNourianz for controlling "OFF" events in PD patients who are being treated with Levodopa/Carbidoba was demonstrated in four 12-week placebo-controlled clinical studies, which were in a total of 1,143 patientsIn all four studies, patients treated with Nourianz had significantly fewer baseline levels in terms of daily "OFF" time than those who took a placeboIn the study, the most common adverse reactions in patients taking Nourianz were involuntary muscle movement (movement disorder), dizziness, constipation, nausea, hallucinations, and insomniaIt is important to note that when using Nourianz therapy, patients should be monitored for increased movement disorders or existing motor disordersIf there is hallucinations, psychotic behavior, or impulsive/coercive behavior, you should consider reducing the dose or stopping using Nourianz In addition, Nourianz is not recommended during pregnancy Female patients with fertility potential are advised to use the pill during treatment.　　Recently, the Japanese pharmaceutical company Concord Kirin announced the launch of The New Parkinson's drug Nourianz (istradefylline tablets) in the United States 　　Nourianz was approved by the U.S FDA at the end of August 2019 as an additional treatment for left-handed doba/cabidoba for adult patients with Parkinson's disease (PD) who are experiencing a "OFF event" event 　　In December 2018, Acorda's product Inbrija (Left-handed Doba Inhalation Powder) was approved by the U.S FDA for intermittent treatment of PD events in PD patients treated with Cabidoba/Left-handed doba Inbrija is the FDA-approved first inhaled levodopa product, a combination of drugs and devices that allows patients to deliver their own hand-held medicines 　　Inbrija has been developed using Acorda's proprietary ARCUS platform to provide accurate doses of l-doba dry powder preparations to the patient's lungs In oral cases, the drug is absorbed through the stomach before reaching the brain, so the process of starting the action changes Inhalation therapy can enter the body through the lungs, reaching directly into the brain and bypassing the digestive system 　　About istradefylline
istradefylline is an oral administration of selective adenosine A2A receptor antagonists, adenosine is a widely distributed in the human body neuromodulator, adenosine A2A receptor belongs to the G protein conjugate receptor In the brain, adenosine A2A receptors are found in the fundamental synostic nerve The effectiveness of the basal nerve section in Nourianz for controlling "OFF" events in PD patients who are being treated with Levodopa/Carbidoba was demonstrated in four 12-week placebo-controlled clinical studies, which were in a total of 1,143 patients In all four studies, patients treated with Nourianz had significantly fewer baseline levels in terms of daily "OFF" time than those who took a placebo 　　In the study, the most common adverse reactions in patients taking Nourianz were involuntary muscle movement (movement disorder), dizziness, constipation, nausea, hallucinations, and insomnia notes
note that when using Nourianz therapy, patients should be monitored for increased movement disorders or existing motor disorders If there is hallucinations, psychotic behavior, or impulsive/coercive behavior, you should consider reducing the dose or stopping using Nourianz 　　In addition, Nourianz is not recommended during pregnancy Female patients with fertility potential are advised to use the pill during treatment